2nd Quarter - Termination

WILLIAMS AND JENSEN, PLLC for VERTEX PHARMACEUTICALS INCORPORATED

Firm
Client
Income
$20,000
Expenses
—
Terminated
May 31, 2023

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

General education about federal policies impacting pharmaceutical development, approval, and reimbursement.

LobbyistCovered position, as disclosed
KARINA LYNCH New Staff, Senate Special Committee on Aging; Staff, Senate Committee on Government Affairs; Senate Committees on Aging and Gov. Affairs

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Medical/Disease Research/Clinical Labs MED

General education about federal policies impacting pharmaceutical development, approval, and reimbursement.

LobbyistCovered position, as disclosed
KARINA LYNCH New Staff, Senate Special Committee on Aging; Staff, Senate Committee on Government Affairs; Senate Committees on Aging and Gov. Affairs

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Medicare/Medicaid MMM

General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Implementation of P.L. 117-169 provisions related to Medicare prescription drugs. Education about non-opioid pain therapies.

LobbyistCovered position, as disclosed
KARINA LYNCH New Staff, Senate Special Committee on Aging; Staff, Senate Committee on Government Affairs; Senate Committees on Aging and Gov. Affairs

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Budget/Appropriations BUD

General education about policies to improve outcomes for patients with APOL-1 kidney disease.

LobbyistCovered position, as disclosed
KARINA LYNCH New Staff, Senate Special Committee on Aging; Staff, Senate Committee on Government Affairs; Senate Committees on Aging and Gov. Affairs

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.